BIOL Biolase Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIOL

Price (delayed)

$0.3306

Market cap

$2.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.57

Enterprise value

$6.62M

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and ...

Highlights
Biolase's revenue has increased by 33% YoY and by 6% from the previous quarter
BIOL's debt is down by 6% year-on-year
BIOL's gross profit is up by 30% year-on-year but it is down by 12% since the previous quarter
The company's EPS has shrunk by 75% YoY and by 19% QoQ
Biolase's quick ratio has plunged by 61% YoY and by 41% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.biolase.com
Peers: ALGN XRAY PDEX

Key stats

What are the main financial stats of BIOL
Market
Shares outstanding
7.15M
Market cap
$2.36M
Enterprise value
$6.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.16
Price to sales (P/S)
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.14
Earnings
Revenue
$46.82M
EBIT
-$22.17M
EBITDA
-$21.69M
Free cash flow
-$27.85M
Per share
EPS
-$3.57
Free cash flow per share
-$3.66
Book value per share
$2.02
Revenue per share
$6.15
TBVPS
$5.24
Balance sheet
Total assets
$42.87M
Total liabilities
$29.01M
Debt
$14.22M
Equity
$13.86M
Working capital
$20.12M
Liquidity
Debt to equity
1.03
Current ratio
2.46
Quick ratio
1.08
Net debt/EBITDA
-0.2
Margins
EBITDA margin
-46.3%
Gross margin
36.8%
Net margin
-51.4%
Operating margin
-45.6%
Efficiency
Return on assets
-48.7%
Return on equity
-119.4%
Return on invested capital
-80.4%
Return on capital employed
-76.2%
Return on sales
-47.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOL stock price

How has the Biolase stock price performed over time
Intraday
-0.39%
1 week
-15.23%
1 month
-27.34%
1 year
-96.24%
YTD
-49.14%
QTD
-49.14%

Financial performance

How have Biolase's revenue and profit performed over time
Revenue
$46.82M
Gross profit
$17.22M
Operating income
-$21.34M
Net income
-$24.05M
Gross margin
36.8%
Net margin
-51.4%
BIOL's net income is down by 41% year-on-year and by 27% since the previous quarter
Biolase's revenue has increased by 33% YoY and by 6% from the previous quarter
BIOL's operating income is down by 31% since the previous quarter and by 22% year-on-year
BIOL's gross profit is up by 30% year-on-year but it is down by 12% since the previous quarter

Growth

What is Biolase's growth rate over time

Valuation

What is Biolase stock price valuation
P/E
N/A
P/B
0.16
P/S
0.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.14
The company's EPS has shrunk by 75% YoY and by 19% QoQ
BIOL's price to book (P/B) is 97% less than its 5-year quarterly average of 6.0 and 92% less than its last 4 quarters average of 1.9
The equity has shrunk by 54% YoY and by 36% QoQ
The stock's price to sales (P/S) is 96% less than its 5-year quarterly average of 1.2 and 95% less than its last 4 quarters average of 1.0
Biolase's revenue has increased by 33% YoY and by 6% from the previous quarter

Efficiency

How efficient is Biolase business performance
BIOL's ROE has shrunk by 82% YoY and by 52% QoQ
The return on assets has dropped by 56% year-on-year and by 36% since the previous quarter
Biolase's ROIC has decreased by 37% YoY and by 23% from the previous quarter
The company's return on sales fell by 24% QoQ and by 14% YoY

Dividends

What is BIOL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOL.

Financial health

How did Biolase financials performed over time
The company's total assets is 48% higher than its total liabilities
Biolase's quick ratio has plunged by 61% YoY and by 41% from the previous quarter
The current ratio has declined by 37% year-on-year and by 22% since the previous quarter
BIOL's debt is 2.6% greater than its equity
The debt to equity has soared by 106% YoY and by 56% from the previous quarter
The equity has shrunk by 54% YoY and by 36% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.